Advertisement

Topics

Celgene’s $710M Gamble On A Crohn’s Disease Drug Ends In Defeat

09:46 EDT 23 Oct 2017 | Pharmaceutical Processing

American biotech company Celgene recently announced that it has prematurely halted a phase three clinical trial for a drug called mongersen.
Staff Author: 

Original Article: Celgene’s $710M Gamble On A Crohn’s Disease Drug Ends In Defeat

NEXT ARTICLE

More From BioPortfolio on "Celgene’s $710M Gamble On A Crohn’s Disease Drug Ends In Defeat"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...